Protein Sciences Receives Approval from FDA for 2014/15 Formulation of Flublok® Influenza Vaccine

July 8, 2014 Protein Sciences Corporation announced today that the FDA has approved the Company’s strain change amendment for its seasonal influenza vaccine, Flublok. Every year influenza vaccine manufacturers must receive approval from the Agency for changes they make to the upcoming season’s manufacturing process and product formulation, as the influenza vaccine is adapted annually. Early approval for Flublok will …

Protein Sciences Adds Distributor for Flublok® Recombinant Influenza Vaccine to Increase Access

June 10, 2014 Protein Sciences Corporation announced it will have more doses, earlier availability and broader distribution coverage of its modern, egg-free Flublok® Influenza Vaccine for the 2014/2015 season. Up to 500,000 doses of the vaccine will be manufactured, and the first doses will be available in September. ASD Specialty Healthcare and its Besse Medical and Oncology Supply divisions have …

FluBlok®: Gaining Regulatory Approval Following Phase 3 Studies

FluBlok® is one of many vaccines in development in the fight against flu. Dan Adams, Executive Chairman, Global Head of Business Development, Protein Sciences Corporation presented a case study at the World Influenza Congress in 2011, discussing his company's product FluBlok®: Gaining Regulatory Approval Following Phase 3 Studies. His presentation was structured around the following points: •    Company overview: business …